Virginie Jego

Survival in idursulfase‐treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS)

Barbara K. Burton, Virginie Jego, Jaromir Mikl et al. · Journal of Inherited Metabolic Disease · 2017 · 89 citations · Full text

Life Sciences, Internal Medicine, Neurology +12

Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)

Joseph Muenzer, Roberto Giugliani, Maurizio Scarpa et al. · Orphanet Journal of Rare Diseases · 2017 · 85 citations · Full text

Life Sciences, Pharmacotherapy, Clinical Epidemiology +7

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

Teresa Macarulla, Andrés Cervantes, Josep Tabernero et al. · British Journal of Cancer · 2015 · 33 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors

Monica Mita, Michael S. Gordon, N. Rejeb et al. · Targeted Oncology · 2013 · 17 citations

Medicine, Oncology, Pharmacology +14

Intrafamilial variability in the clinical manifestations of mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS)

Roberto Giugliani, Paul Harmatz, Nancy J. Mendelsohn et al. · American Journal of Medical Genetics Part A · 2017 · 17 citations · Full text

Life Sciences, Genetics, Genodermatoses +4